We’re pleased to share the Q1 2025/26 network highlights report.
It covers our submission on the Draft Disability Strategy 2026–2030, informed by chairs across Neurodevelopmental, General Paediatrics, and Child Protection, with a focus on improving outcomes for Aotearoa’s 98,000 children with disabilities.
It also outlines support for PHARMAC’s proposal to fund Methylphenidate Sandoz XR from 1 December 2025, and advocacy from the Diabetes Network backing the removal of Special Authority renewals while urging CGM inclusion to better serve more than 18,000 eligible patients, including 2,500+ tamariki and rangatahi.
Read the full summary and submissions in the attached report.